Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.

IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL
Laxmi Banjare
{"title":"Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.","authors":"Laxmi Banjare","doi":"10.2174/0118715206265278231026101739","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In current scenario breast cancer measured as one of the dangerous health issues. An effective therapeutic class of drug known as aromatase inhibitors (AIs) is dominant against estrogen receptorpositive breast cancer. However, there is an urgent need to create target-specific AIs with better anti-breast cancer profiles due to the increased toxicity and adverse effects related to currently existing anti-breast cancer drugs.</p><p><strong>Objectives: </strong>In the present study, we have designed of 100 novel tiazole analogues as aromatase inhibitors their pharmacophoric features were explored.</p><p><strong>Method: </strong>Molecular docking was applied to a series of 4-substituted-1, 2, 3-triazoles containing letrozole for their aromatase inhibitory effects. The aromatase inhibitory activity of the compound in a series varies in the range of (IC<sub>50</sub> = 0.008-31.26 μM). A hydrogen atom positioned at R1 of the triazole ring in compound (01) was responsible for the most potent compound (IC<sub>50</sub> = 0.008 μM) in the series of 28 compounds as compared to letrozole. The self-organizing molecular field study was used to assess the molecular characteristics and biological activities of the compounds. The four models were developed using PLS and MLR methods. The PLS method was good for statistical analysis. The letrozole scaffold-based 100 compounds were designed by selecting an effective pharmacophore responsible for aromatase inhibitory activity. The designed compound was placed on the previous model as a test set, and its IC<sub>50</sub> values were calculated.</p><p><strong>Result: </strong>Hydrogen bonds were established between the potent molecule (01) and the essential residues Met 374 and Arg 115, which were responsible for the aromatase-inhibiting action. Cross-validated q2 (0.6349) & noncross- validated r2 (0.7163) were discovered in the statistical findings as having reliable predictive power. Among 100 designed compounds, seven compounds showed good aromatase inhibitory activities.</p><p><strong>Conclusion: </strong>The additional final SOMFA model created for the interactions between the aromatase and the triazole inhibitors may be helpful for future modification and enhancement of the inhibitors of this crucial enzyme.</p>","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":" ","pages":"288-303"},"PeriodicalIF":2.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715206265278231026101739","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In current scenario breast cancer measured as one of the dangerous health issues. An effective therapeutic class of drug known as aromatase inhibitors (AIs) is dominant against estrogen receptorpositive breast cancer. However, there is an urgent need to create target-specific AIs with better anti-breast cancer profiles due to the increased toxicity and adverse effects related to currently existing anti-breast cancer drugs.

Objectives: In the present study, we have designed of 100 novel tiazole analogues as aromatase inhibitors their pharmacophoric features were explored.

Method: Molecular docking was applied to a series of 4-substituted-1, 2, 3-triazoles containing letrozole for their aromatase inhibitory effects. The aromatase inhibitory activity of the compound in a series varies in the range of (IC50 = 0.008-31.26 μM). A hydrogen atom positioned at R1 of the triazole ring in compound (01) was responsible for the most potent compound (IC50 = 0.008 μM) in the series of 28 compounds as compared to letrozole. The self-organizing molecular field study was used to assess the molecular characteristics and biological activities of the compounds. The four models were developed using PLS and MLR methods. The PLS method was good for statistical analysis. The letrozole scaffold-based 100 compounds were designed by selecting an effective pharmacophore responsible for aromatase inhibitory activity. The designed compound was placed on the previous model as a test set, and its IC50 values were calculated.

Result: Hydrogen bonds were established between the potent molecule (01) and the essential residues Met 374 and Arg 115, which were responsible for the aromatase-inhibiting action. Cross-validated q2 (0.6349) & noncross- validated r2 (0.7163) were discovered in the statistical findings as having reliable predictive power. Among 100 designed compounds, seven compounds showed good aromatase inhibitory activities.

Conclusion: The additional final SOMFA model created for the interactions between the aromatase and the triazole inhibitors may be helpful for future modification and enhancement of the inhibitors of this crucial enzyme.

三唑类似物作为芳香化酶抑制剂的设计和药效团研究。
背景:在目前的情况下,癌症被视为最危险的健康问题之一。一种被称为芳香化酶抑制剂的有效治疗药物对雌激素受体阳性的乳腺癌症占主导地位。然而,由于目前存在的抗癌症药物的毒性和不良反应增加,迫切需要创建具有更好抗乳腺癌症特征的靶向特异性AI。目的:在本研究中,我们设计了100种新的硫唑类似物作为芳香化酶抑制剂,并探讨了它们的药效学特征。方法:将分子对接技术应用于一系列含有来曲唑的4-取代-1,2,3-三唑类化合物中,考察其对芳香化酶的抑制作用。一系列化合物的芳香化酶抑制活性在(IC50=0.008-31.26µM)范围内变化。与来曲唑相比,化合物(01)中位于三唑环R1的氢原子是28种化合物系列中最有效的化合物(IC50=0.008µM)。自组织分子场研究用于评估连续物质的分子特征和生物活性。这四个模型是根据PLS和MLR方法开发的。PLS方法具有良好的统计分析效果。通过选择负责芳香化酶抑制活性的有效药效团,设计了基于来曲唑支架的100个化合物。将设计的化合物放置在先前的SOMFA模型上作为测试集,并计算它们的IC50值。结果:强分子(01)与必需残基Met 374和Arg 115之间建立了氢键,起到抑制芳香化酶的作用。统计结果中发现,交叉验证的q2(0.6349)和非交叉验证的r2(0.7163)具有可靠的预测能力。在设计的100个化合物中,有7个化合物显示出良好的芳香化酶抑制活性。结论:为该酶和来曲唑阻滞剂之间的相互作用创建的额外的最终SOMFA模型可能有助于未来修饰和增强该关键酶的抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anti-cancer agents in medicinal chemistry
Anti-cancer agents in medicinal chemistry ONCOLOGY-CHEMISTRY, MEDICINAL
CiteScore
5.10
自引率
3.60%
发文量
323
审稿时长
4-8 weeks
期刊介绍: Formerly: Current Medicinal Chemistry - Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents. Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication. Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信